Pharma Industry

Favipiravir has limited efficacy data, but doctors still go for Glenmark’s drug to cope with a crisis



Last month, India’s drug regulator granted emergency-use authorisation for favipiravir to treat Covid-19, making it the first oral anti-viral drug approved for such use. However, Glenmark, which launched the favipiravir brand FabiFlu, hasn’t yet disclosed data of its clinical trial on 150 patients to assess the drug’s safety and efficacy. This is causing concern among doctors and public-health experts.

Desperate times call for desperate measures. The count of India’s Covid-19 cases has crossed 1.1 million, with around 30,000 cases being added daily. Total deaths so far have been 28,084. The situation is grim and the end nowhere in sight. With its back to the wall, the country has been forced to take a few risks. But what’s critical is the trade-off and its extent. Doctors are facing this dilemma every day because a large number of drugs are

  • SAVE

Sign in to read the full article

You’ve got this Prime Story as a Free Gift

Already a Member?

Why ?

  • Sharp Insight-rich, Indepth stories across 20+ sectors

  • Access the exclusive Economic Times stories, Editorial and Expert opinion

  • Clean experience with
    Minimal Ads

  • Comment & Engage with ET Prime community

  • Exclusive invites to Virtual Events with Industry Leaders

  • A trusted team of Journalists & Analysts who can best filter signal from noise


Source link